Sparsentan
Sparsentan is a dual-action antihypertensive medication that blocks both endothelin type A and angiotensin II type 1 receptors to protect kidney function. It is FDA-approved for treating focal segmental glomerulosclerosis (FSGS), a rare kidney disease characterized by scarring of the kidney's filtering units, and is also being studied for other proteinuric kidney diseases.
Sparsentan is a dual endothelin and angiotensin receptor blocker used to treat focal segmental glomerulosclerosis by reducing proteinuria and slowing kidney disease progression.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- C09XX01
- RxNorm
- 2630535
- Generic
- Sparsentan
- Class
- atc-c09
- Brands
- Filspari
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Sparsentan is approved for treating focal segmental glomerulosclerosis (FSGS) in adults to reduce proteinuria. It is also under investigation for other proteinuric kidney diseases such as IgA nephropathy.
Sparsentan works by simultaneously blocking endothelin type A receptors (ETAR) and angiotensin II type 1 receptors (AT1R). This dual antagonism reduces glomerular inflammation, fibrosis, and oxidative stress, thereby protecting kidney structures and reducing protein loss in urine.
Sparsentan requires regular liver function monitoring due to hepatotoxicity risk. It is contraindicated in pregnancy (teratogenic) and requires monthly pregnancy testing in women of childbearing potential. Common adverse effects include peripheral edema, hypotension, and dizziness. Patients should be counseled on signs of liver injury and fluid retention.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy